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Inflammation and bone 
mineral density: A Mendelian 
randomization study
Jian V. Huang1 & C. Mary Schooling  1,2
Osteoporosis is a common age-related disorder leading to an increase in osteoporotic fractures and 
resulting in significant suffering and disability. Inflammation may contribute to osteoporosis, as it 
does to many other chronic diseases. We examined whether inflammation is etiologically relevant to 
osteoporosis, assessed from bone mineral density (BMD), as a new potential target of intervention, or 
whether it is a symptom/biomarker of osteoporosis. We obtained genetic predictors of inflammatory 
markers from genome-wide association studies and applied them to a large genome wide association 
study of BMD. Using two-sample Mendelian randomization, we obtained unconfounded estimates 
of the effect of high-sensitivity C-reactive protein (hsCRP) on BMD at the forearm, femoral neck, 
and lumbar spine. After removing potentially pleiotropic single nucleotide polymorphisms (SNPs) 
possibly acting via obesity-related traits, hsCRP, based on 16 SNPs from genes including CRP, was not 
associated with BMD. A causal relation of hsCRP with lower BMD was not evident in this study.
Osteoporosis increases the risk of fracture. Bone mineral density (BMD), a biomarker of osteoporosis, is a risk 
factor for fracture which contributes to the global burden of disease from falls1. Between 1990 and 2010, global 
deaths and disability-adjusted life years attributable to low BMD increased, probably due to the aging global 
population1. The burden of osteoporosis (BMD 2.5 standard deviations (SDs) below the reference, i.e. the mean 
in healthy young adult women2) and osteopenia (BMD 1.0–2.5 SDs below the reference)2 among older adults is 
projected to rise in the coming decade, for example in the United States and Australia3, 4. Apart from the effects 
on population health, this escalating global burden of osteoporotic disorders places an increasing burden on 
healthcare providers4–6, because falls and fractures in older people can generate long hospital stays, extensive con-
valescence and permanent disability. Inflammation plays an important role in many major non-communicable 
diseases7–9, and is increasingly realized to be relevant to the bone remodeling10 that precedes osteoporosis11.
In a recent epidemiological study, older men (aged 65 years or above) with three or more inflammatory mark-
ers in the top quartile had a higher risk of hip or vertebral fracture, but the specific associations of each inflam-
matory marker with fracture at different skeletal sites varied12. Observational studies have reported associations 
of several major inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6) and monocyte 
chemotactic protein-1 (MCP-1), with osteoporosis and/or osteopenia13–15, but findings have not always been 
consistent16, 17. Moreover, distinguishing between biomarkers and causal factors is difficult in observational stud-
ies, making it unclear whether inflammation is etiologically relevant to osteoporosis as a new potential target of 
intervention, is a symptom or is a correlate of other unmeasured causal factors. The controversy over current 
precautionary treatments for low BMD, such as calcium18, demonstrates the importance of thorough validation 
of targets of intervention, as well as the importance of the discovery of new targets.
In this situation assessing whether people with genetically higher levels of inflammatory markers have lower 
BMD, i.e., Mendelian randomization (MR), provides a way forward. Given genotypes are randomly assorted at 
conception, MR, or instrumental variable analysis with genetic variants, can mimic a randomized controlled trial 
and is becoming an important tool for assessing causal relations in observational studies19, 20. To the best of our 
knowledge, only one previous MR study has assessed the role of inflammation in BMD and fractures. It did not 
find a causal relation of higher high-sensitivity CRP (hsCRP) with higher fracture risk, suggesting hsCRP may 
be a marker of unknown confounders that affect fracture risk21. We used a two-sample MR study to estimate 
the unconfounded associations of several inflammatory markers with BMD. Specifically, we obtained genetic 
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predictors of inflammatory markers from genome-wide association studies (GWAS) and applied them to a GWAS 
of BMD from a large international consortium. Inflammation and obesity have a complex interplay, which a bidi-
rectional MR study clarified as adiposity likely causing higher CRP rather than CRP causing adiposity22. As such, 
we also checked whether the genetic predictors of inflammation also affected adiposity, to exclude potentially 
pleiotropic effects.
Methods
Genetic predictors of inflammatory markers. SNPs predicting inflammatory markers, including 
hsCRP, IL-6, erythrocyte sedimentation rate (ESR) and MCP-1, were obtained from SNPs of genome-wide sig-
nificance (p < 5 × 10−8) from the largest available published GWAS. Correlations between these SNPs (linkage 
disequilibrium (LD)) were obtained from SNP Annotation and Proxy Search (SNAP) (http://www.broadinstitute.
org/mpg/snap/ldsearchpw.php) using the 1000 genomes reference panel. Highly correlated SNPs (r2 ≥ 0.8) for 
each exposure were discarded to retain SNPs with the smallest p-values. A SNP highly correlated with the origi-
nal SNP was used as proxy when the original SNP was not available in GEFOS. When the remaining SNPs for an 
exposure were correlated an LD matrix was built and included in the MR analysis to account for that correlation. 
MR studies assume that the SNPs (instrumental variables) are associated with the outcome only via the expo-
sure23, so we performed sensitivity analysis excluding SNPs with potentially pleiotropic effects. Ensembl (http://
www.ensembl.org) integrates genome annotation with available biological data, and provides the phenotypes 
associated with a given SNP. We manually searched Ensembl for the phenotypes associated with each SNP. SNPs 
with phenotypes that may affect BMD other than via the relevant exposure were considered as having potentially 
pleiotropic effects.
Genetic predictors of BMD. Genetic associations with BMD were contributed by the GEnetic Factors for 
OSteoporosis (GEFOS) Consortium (http://www.gefos.org). The GEFOS-seq project investigated the associa-
tions of SNP with BMD in a general population of European descent (N = 32,965)24. Genetic associations with 
BMD for SNPs with a minor allele frequency ≥ 0.5% in an additive model adjusted for age, age-squared, sex, and 
weight24 were made publically available in 201525. BMD was measured using Dual-energy X-ray Absorptiometry 
at three skeletal sites, the forearm (distal 1/3 of radius), lumbar spine (L1-4) and femoral neck24. BMD within 
each study was standardized to account for systematic differences between Dual-energy X-ray Absorptiometry 
machines24.
Statistical Analysis. SNPs predicting the exposures (i.e. inflammatory markers) were used as instrumental 
variables in two-sample MR to obtain unconfounded estimates of the effects of hsCRP, IL-6, ESR, and MCP-1 on 
BMD (SD units) at the forearm, femoral neck, and lumbar spine. To obtain an overall estimate for each exposure, 
we combined SNP-specific Wald estimates using inverse variance weighting with the standard error calculated as 
the ratio of the standard error of SNP on outcome to the estimate of SNP on exposure. We used fixed effects when 
only three or fewer SNPs were available, and used random effects when four or more SNPs were available. Where 
SNPs for a particular exposure were correlated, we used generalized weighted linear regression and a matrix of 
their correlations. In order to assess the robustness of these findings, we used a weighted median (WM) estimate, 
which is consistent when up to 50% of the SNPs are invalid instrumental variables26. We also used MR-Egger 
to test for potentially pleiotropic effects as it may generate correct estimates even when all SNPs are invalid 
instruments as long as the assumption of instrument strength independent of direct effect (InSIDE) is satisfied. 
Average directional pleiotropy across genetic variants was assessed from the p-value of the intercept term from 
MR-Egger26. Analysis using MR-Egger has a lower false positive rate but a higher false negative rate than IVW27. 
We also similarly checked the associations of the SNPs predicting inflammation with obesity-related traits from 
the largest available GWAS among people of European descent in the Genetic Investigation of ANthropometric 
Traits (GIANT) consortium databases28–30, and Early Growth Genetics (EGG) consortium database31. SNPs with 
potentially pleiotropic effects were excluded in an additional analysis. We used a p-value of 0.0125 as significance 
threshold, because we performed MR analysis for four inflammatory markers, i.e. hsCRP, IL-6, ESR, and MCP-1.
All statistical analyses were conducted using R version 3.3.0 (R Foundation for Statistical Computing, Vienna, 
Austria) and MR analyses were performed using the MendelianRandomization package. This study only used 
publicly available summary data and hence no ethical approval from an Institutional Review Board was required.
Results
The largest available GWAS for hsCRP identified 20 SNPs (from genes including CRP, IL-6R, and LEPR) predict-
ing natural log-transformed CRP from two studies of 194,418 (mean age 59 years)32 and 66,185 (mean age 55 
years)33 people of European descent34. Among these 20 SNPs, 6 proxy SNPs were used, i.e., rs3116656 (Intergenic 
variant) as a proxy SNP for rs1130864 (CRP), rs11065385 (HNF1A) for rs1183910 (HNF1A), rs780094 (GCKR) 
for rs1260326 (GCKR), rs77013776 (intergenic variant) for rs1800947 (CRP), rs61812598 (IL6R) for rs4129267 
(IL6R), and rs993394 (GPRC6A) for rs6901250 (GPRC6A).
A GWAS by Naitza et al. provides genetic predictors of IL-6, ESR, and MCP-1 (in SD units) based on 4292, 
3596, and 4295 people respectively aged 14–102 years from the Lanusei Valley of Sardinia, Italy35, 36. Four SNPs 
from ABO were used to predict IL-6 (3 SNPs in the analysis of each skeletal site). Two proxy SNPs were used, i.e. 
rs657152 (ABO) as a proxy for rs643434 (ABO) and rs544873 as a proxy for rs687289 (ABO). However, highly 
pleiotropic effects of ABO cast doubt on whether these SNPs solely affect BMD via IL-6. We repeated the analysis 
for IL-6 using SNPs from two other sources. Three SNPs in IL6R, predicting natural log-transformed IL-6, were 
obtained from a previous MR study by the IL-6R MR Analysis Consortium in 4489 Europeans37. rs61812598 
(IL6R) was used as a proxy for rs7529229 in the analysis of BMD at the femoral neck and lumbar spine. Another 
three SNPs predicting IL-6 (from KPNB1, SERPINE2, TC2N) were obtained from a GWAS by Ahola-Olli et al. in 
www.nature.com/scientificreports/
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1664 Finns38. Four SNPs from CR1 were used to predict ESR, of which 3 were included in the analysis of BMD at 
the femoral neck and lumbar spine respectively. Twenty-three SNPs were used to predict MCP-1 (from ACKR1, 
AIM2, CADM3, DUSP23, FCER1A, OR10J1, OR10J2P, OR10J7P, OR10J9P, and intergenic variant), among which 
22 were included in the analysis of BMD at the femoral neck and lumbar spine respectively. rs79433881 (OR10J1) 
was used as a proxy for rs11265186 (OR10J9P) in the analysis of BMD at the femoral neck, and rs4290055 was 
used as a proxy for rs11265186 (OR10J9P) in the analysis of BMD at the lumbar spine.
We matched the chosen SNPs with GWAS of obesity-related traits and found none of the SNPs achieved 
genome-wide significance in GIANT or EGG (Table 1 in the Supplementary material). Nevertheless, some of 
these SNPs (rs1260326 (GCKR), rs13233571 (BCL7B), rs2847281 (PTPN2), and rs4129267 (IL6R) predict-
ing hsCRP and rs630014 (ABO), rs651007 (ABO), and rs687289 (ABO) predicting IL-6) were associated with 
obesity-related traits (Table 2 in the Supplementary material). None of the individual SNPs predicting MCP-1 
were associated with obesity-related traits, but the IVW estimate showed potential associations of MCP-1 
with higher BMI in men and higher risk of obesity class 3 (Table 3 in the Supplementary material). rs12075 
(DARC/CADM3) that predicted MCP-1 also has potential pleiotropic effects on obesity-related traits based on a 
comprehensive search of Ensembl.
Funnel plots for hsCRP, IL-6, ESR, and MCP-1 show some asymmetry (Figures 1 to 4 in the Supplementary 
material). Figures 5 to 8 in the Supplementary material show the scatter plots for hsCRP, IL-6, ESR, and MCP-1. 
We performed analyses including all available SNPs and sensitivity analyses excluding SNPs with potentially 
pleiotropic effects such as SNPs in the pleiotropic genes GCKR and ABO. Table 1 shows the estimates of the effects 
on BMD. hsCRP was not associated with BMD in any model. Figure 1 shows the SNP-specific associations and 
MR estimates for hsCRP. Considering the limitations of the SNPs predicting IL-6, ESR, and MCP-1, estimates for 
these exposure are only presented in Table 4 and Figures 9 to 11 in the Supplementary material. MCP-1 was asso-
ciated with lower BMD at the forearm, but with higher BMD at the femoral neck and lumbar spine. However, the 
association of MCP-1 with BMD at the forearm was no longer evident after removing rs12075 (DARC/CADM3) 
in a sensitivity analysis (Table 4 in the Supplementary material). Intercepts from MR-Egger showed little direc-
tional pleiotropy, but the direction of effect estimates was not always consistent for both IVW and WM.
Discussion
For the first time, we assessed the associations of four major inflammatory markers (i.e. hsCRP, IL-6, ESR, and 
MCP-1) with BMD using two-sample MR to provides unconfounded estimates because genotypes are randomly 
assorted at conception and usually unaffected by the confounders that typically bedevil epidemiological studies, 
such as socio-economic position and health status. Use of two different samples for the exposures and outcomes 
also minimizes susceptibility to confounding because of the different underlying data structures in each sample39. 
We only used SNPs strongly associated with inflammatory markers from the largest available GWAS to reduce 
the risk of false positives, and we used LD matrices to account for any correlation between SNPs predicting each 
exposure. We also checked for potentially pleiotropic effects and removed them in sensitivity analyses. We did not 
observe associations of higher hsCRP with lower BMD.
Although we checked the assumptions of MR rigorously, some limitations exist. First, genetic predictors of 
IL-6, ESR, and MCP-1 were based on an isolated population in the Lanusei Valley of Sardinia, Italy36. These results 






All SNPs Excluding potentially pleiotropic SNPsf
No. of 
SNPsc Methodd β P-valuee
MR-Egger No. of 
SNPsb Method β P-valuee
MR-Egger
Intercept P-value Intercept P-value
hsCRP Prins et al.
Forearm
20 IVW −0.018 0.692 16 IVW 0.009 0.857
20 WM 0.011 0.838 16 WM 0.012 0.828
20 MR-Egger 0.076 0.337 −0.011 0.144 16 MR-Egger 0.054 0.506 −0.006 0.487
Femoral neck
20 IVW −0.035 0.215 16 IVW −0.025 0.298
20 WM −0.016 0.580 16 WM −0.016 0.574
20 MR-Egger 0.015 0.729 −0.006 0.158 16 MR-Egger −0.014 0.726 −0.001 0.749
Lumbar spine
20 IVW −0.038 0.298 16 IVW −0.032 0.402
20 WM −0.054 0.119 16 WM −0.056 0.121
20 MR-Egger −0.064 0.237 0.003 0.560 16 MR-Egger −0.074 0.184 0.005 0.355
Table 1. Estimates of the effects of hsCRP on bone mineral density (in standard deviations) at forearm, femoral 
neck, and lumbar spine provided by GEFOS. aIn the MR study of Prins et al., hsCRP was analysed on a natural 
log scale in mg/L. bBone mineral density was measured as the standard deviation (SD) from the healthy young 
adult reference. cNumber of SNPs included in the analysis of one markers at different skeletal sites may differ, 
because particular SNPs may not be available in GEFOS of specific skeletal site. dInverse-variance weighted 
(IVW), weighted median (WM), and MR-Egger were performed for testing the robustness of the association; 
WM and MR-Egger are only feasible with more than two SNPs. eAssociations with a p-value smaller than 0.0125 
were in bold. fSNPs with potentially pleiotropic effects related to obesity were excluded from the sensitivity 
analysis, including rs1260326 (GCKR), rs13233571 (BCL7B), rs2847281 (PTPN2), and rs4129267 (IL6R) for 
hsCRP.
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more than 4 SNPs were available for IL-6 and ESR, meaning the results for these exposures should be interpreted 
with caution. However, we repeated the analyses for IL-6 using SNPs from IL-6R MR Analysis Consortium and 
the GWAS by Ahola-Olli et al., and found similar results. Second, the specific effect of SNPs on a phenotype may 
be compensated for during development, i.e. canalisation, meaning that the effect of an intervention might not 
mirror the genetic association20, however whether such canalisation exists is unknown. Third, estimates may be 
sensitive to the choice of MR estimator. To test robustness, we also used WM and MR-Egger methods. The esti-
mates were generally similar, but MR-Egger estimates had much wider confidence intervals, and WM with 3 or 4 
SNPs may not return meaningful results. Fourth, statistical power of MR studies needs particular consideration, 
Figure 1. SNP-specific associations of hsCRP (Prins et al.) with bone mineral density (BMD) at each skeletal 
site.
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given that genetic instruments may only explain a small amount of variation of the phenotype40. We were una-
ble to calculate the power for this study because the GWAS of Naitza et al. and of Prins et al. did not report the 
explanation power of SNPs on inflammatory markers. However, one advantage of two-sample MR is increased 
statistical power41. We also estimated the F-statistics based on the effect allele frequency, estimated SNP effect on 
exposure, and sample size42. F-statistics range from 32 to 4419, except for the three SNPs from Ahola-Olli et al., 
which had F-statistics ranging from 3 to 8 (Table 5 in the Supplementary material). An F-statistic higher than the 
conventional threshold of 10 is usually taken as implying little weak instrument bias. Fifth, associations of higher 
genetically predicted MCP-1 with lower BMD were only observed at the femoral neck and lumbar spine. Given 
that BMD is likely to be correlated at different skeletal sites, this may suggest chance findings. Sixth, local and sys-
temic inflammation may impact bone growth via different pathways43, which we could not distinguish. Seventh, 
GEFOS is based on the general population, but osteoporosis is more prevalent among the elderly. However, bone 
loss may start in middle age and increase the risk of osteoporosis and fracture in later life. Lastly, while the prev-
alence of osteoporosis is higher in women, sex-specific analysis was not possible in this study, although causal 
relations are usually consistent.
Previous observational studies have reported inconsistent associations of inflammatory markers with BMD13, 16, 17, 44. 
Inflammation may affect BMD via the bone remodeling cycle regulated by osteoblasts and osteoclasts45 affecting 
osteocalcin46. Previous studies have observed inverse associations of hsCRP with serum osteocalcin47, 48, which 
may play a role in osteoclastogenesis49. However, an in vitro study suggested that CRP inhibits both osteoblast 
and osteoclast differentiation50. Hence, the impact of these inflammatory markers on BMD is unclear. SNPs pre-
dicting hsCRP with potentially pleiotropic effects via obesity-related traits were identified in our study, which 
may imply that the previously reported associations of inflammation with BMD are not causal. Also, higher 
follicle-stimulating hormone is associated with both bone loss51 and higher levels of inflammatory markers 
including CRP and MCP-152, implying a possible confounder of the association of inflammation with bone loss.
A causal relationship of hsCRP with lower BMD was not evident in this study. A replication in the UK Biobank 
would help clarify whether these null findings are due to lack of power or indicate no effect and that other means 
of preventing osteoporosis should be sought.
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